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A WEB-BASED SYSTEM SUPPORTING STRATEGICAL DECISIONS IN
WORLD WIDE URELATED DONOR SEARCH
Feldmann, U.1, Bochtler, W.1, Eberhard, H.-P.1, Mueller, C.R.1
ZKRD Zentrales Knochenmarkspender-Register, Ulm, Germany.
Most active unrelated stem cell donor registries in the world
are participating in the cooperation of Bone Marrow Donors
Worldwide (BMDW). Formally, BMDW is a service provided
by the Dutch registry Europdonor collecting all data, providing
them back to the contributors and making them directly acces-
sible via a web based matching program. Unfortunately, HLA
information is limited for many donors, in particular where
DRB1 alleles are missing or only tested at low or intermediate
resolution. We are using our own copy of the BMDW data to
generate haplotypes frequencies per registry for HLA-A,B-
,DRB1. HLA-A and B are analyzed using serological nomen-
clature and DRB1 using a resolution of 2 and 4 digits as far as
the data for each registry permits. These haplotypes frequencies
are used for a web based system prototyped in our intranet,
which calculates the probability of ﬁnding a donor who is a
match for HLA-A and B (serology) and for DRB1 (allele level)
by performing subsequent test on partially typed donors. In the
calculation of the conditional match probabilities the program
correctly interprets all broad serological designations and mul-
tiple allele codes using the individual frequencies for each reg-
istry. Where there are test candidates in several registries, the
system can also indicate which donors according to their origin
or partial typing status are most likely to turn out to be matches.
This provides a highly intelligent sorting of BMDW match lists.
The program is currently implemented as a CGI-script using
PERL and typically takes 5–20 seconds on a 1.5 GHz XEON
including a full molecular BMDW match run. The program has
immediately become an indispensable tool for the analysis of all
difﬁcult donor searches.
215
COMPARABLE RESULTS OF UMBILICAL CORD BLOOD AND HLA
MATCHED SIBLING DONOR HEMATOPOIETIC STEM CELL TRANSPLANT
AFTER REDUCED-INTENSITY PREPARATIVE REGIMEN FOR ADVANCED
HODGKIN’S LYMPHOMA
Majhail, N.S.1, Defor, T.E.1, Brunstein, C.G.1, Wagner, J.E.1,
Weisdorf, D.J.1, Miller, J.S.1, Arora, M.1, Tomblyn, M.R.1,
McGlave, P.B.1, Slungaard, A.1, Burns, L.J.1 Blood and Marrow
Transplant Program, University of Minnesota, Minneapolis, MN.
The lower regimen-related toxicity of reduced-intensity con-
ditioning (RIC) preparative regimens has extended the oppor-
tunity for allogeneic stem cell transplantation (alloSCT) and its
potential graft-versus-lymphoma effect to patients with ad-
vanced Hodgkin’s lymphoma (HL). In this pilot study, we com-
pared the safety and efﬁcacy of RIC alloSCT in 21 adults with
chemosensitive primary refractory or relapsed HL using either
umbilical cord blood (UCB-9) or matched sibling donors
(MSD-12). Indications for RIC alloSCT were age 	55 years
with HLA matched sibling donor (19%), age 	45 years with
UCB donor (5%), extensive prior therapy including previous
autologous stem cell transplant (ASCT) (67%), or major co-
morbidity (22%). Of the 14 patients who had failed prior ASCT,
median duration of post-transplant CR was 11 months (range,
3–54). Patient demographics, disease characteristics at initial
diagnosis, and at relapse prior to alloSCT were comparable
except for a younger age in the UCB cohort (median 28 years vs
42 years for MSD, P  .04). Results are shown in Table 1.
Neutrophil recovery occurred earlier in the MSD group. All
patients had sustained donor engraftment by day 60. Cumu-
lative incidence of grade III/IV acute graft-versus-host disease
and 180-day treatment-related mortality were comparable. Two
patients who underwent MSD alloSCT received donor-lympho-
cyte infusion for post-transplant relapse with resultant partial
responses lasting 3 and 6 months. With a median follow-up of
17 and 24 months for the UCB and MSD groups, respectively,
the 2-year progression-free survival (PFS) for UCB is 25%
compared to 20% for MSD alloSCT. The median time to
disease progression was 4 months for the UCB group and 6
months for the MD group; all relapses occurred within 1 year of
alloSCT. Patients with relapsed disease or longer post-ASCT
CR (12 months) were more likely to be alive and free of
progressive disease than patients with primary refractory disease
or short CR. Our results suggest comparable outcomes for RIC
alloSCT using UCB or MSD source in adults with high-risk,
advanced HL. Since many patients lack a matched sibling or
unrelated donor, UCB grafts can provide an effective and safe
alternative. In addition, alloSCT using RIC is associated with
durable PFS in a selected subgroup of patients. Further studies
are ongoing to identify patients who would beneﬁt the most by
this approach (Table 1).
Table 1. Post-Transplant Outcomes
UCB
(n  9)
MSD
(n  12)
P-
Value
Cell dose (107
NC/kg)
Median
(range)
3.8 (2.3–5.3) 10.0 (7.9–16.4) <.01
HLA 1–2
antigen
mismatch
9 (100%) 1 (8%) <.01
Neutrophil
engraftment
(days)
Median
(range)
10 (6–28) 7 (5–12) .02
Complete
donor
chimerism
Day 21 6 (67%) 12 (100%) .06
Day 60 9 (100%) 12 (100%) -
Acute GVHD Grade II–IV 6 (67%) 7 (58%) .70
Grade III–IV 3 (33%) 4 (33%) .99
Chronic GVHD 1 (11%) 4 (33%) .24
CR after
alloSCT
8 (89%) 9 (75%) .42
Treatment
related
mortality
100 days 1 (11%) 2 (17%) .80
180 days 2 (22%) 3 (25%) .88
Followup
(months)
Median (range) 17 (4–51) 24 (9–53)
2-year PFS
(months)
(95% CI) 25% (0–55%) 20% (0–44%) .67
2-year OS
(months)
(95% CI) 51% (16–86%) 48% (19–77%) .93
NC-nucleated cells; HLA-human leukocyte antigem; GVHD-
graft-versus-host-disease; CR-complete remission; CI-conﬁ-
dence intervals.
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MOBILIZATION OF PERIPHERAL BLOOD CD34 STEM CELLS IN A
HEAVILY PRE-TREATED PEDIATRIC MEDULLOBLASTOMA PATIENT US-
ING AMD3100 AND G-CSF
Robertson, K.A.1, Pradhan, K.1, Goebel, S.1, Renbarger, J.1, Abonour, R.1,
Calandra, G.B.2, McFarland, R.T.2, Haut, P.R.1 1. Indiana Univeristy
School of Medicine, Indianapolis, IN; 2. AnorMed Inc., Langley, BC,
Canada.
Autologous peripheral blood stem cell transplantation has
been beneﬁcial in the setting of recurrent medulloblastoma,
however many of these patients are heavily pre-treated, making
conventional mobilization of peripheral blood stem cells with
G-CSF alone difﬁcult. The recent development of AMD3100 as
an inhibitor of the binding of SDF-1/CXCL12 to its receptor
CXCR4 in the marrow stem cell compartment has resulted in
signiﬁcant enhancement in the mobilization of peripheral blood
stem cells. This has met with considerable success in adults with
phase III trials under way, however there is little pediatric
experience with the use of AMD3100. We report here the use of
AMD3100 to mobilize peripheral blood CD34 cells from a
heavily pre-treated 11 year-old girl with recurrent medulloblas-
toma. DM was diagnosed with stage IV medulloblastoma in Feb
2004 and was treated with surgical resection, radiation, and
maintenance chemotherapy including cisplatin, CCNU, and
vincristine. Prior to her 5th cycle of chemotherapy she experi-
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